The content on this site is intended for healthcare professionals only
Immunotherapy trials and hyperprogressive disease
First-in-human phase 1 study of TAK-931 for solid tumours
Web-mediated follow-up via patient-reported outcomes vs. routine surveillance in lung cancer patients
The CAPTIVATE trial of ibrutinib and venetoclax as a first line treatment for CLL patients
Development of blood tests for early lung cancer
Linking Lynch Syndrome and microsatellite instability in tumours
Matching personalised therapies to patients in the IMPACT trial
Atezolizumab with chemotherapy improves PFS in squamous NSCLC
Development of blood tests for early lung cancer
Matching mutations in tumours to precision medicine improves survival
Genomic study links several new cancers to Lynch Syndrome
Atezolizumab with chemotherapy improves PFS in squamous NSCLC
